GCC2-ALK as a targetable fusion in lung adenocarcinoma and its enduring clinical responses to ALK inhibitors.
暂无分享,去创建一个
Xue Wu | Y. Shao | Junhong Jiang | Jianan Huang | Xiaonan Wang | X. Tong | Anan Chen | Wan-Chen Wei
暂无分享,去创建一个
Xue Wu | Y. Shao | Junhong Jiang | Jianan Huang | Xiaonan Wang | X. Tong | Anan Chen | Wan-Chen Wei